Document Detail


Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
MedLine Citation:
PMID:  23349007     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival.
DIAGNOSIS: Diagnosis is based on bone marrow morphology. The presence of fibrosis, JAK2/MPL mutation, or +9/13q- cytogenetic abnormality is supportive but not essential for diagnosis. Prefibrotic PMF mimics essential thrombocythemia in its presentation and the distinction is prognostically relevant. Differential diagnosis of myelofibrosis should include chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
RISK STRATIFICATION: The Dynamic International Prognostic Scoring System-plus (DIPSS-plus) prognostic model for PMF can be applied at any point during the disease course and uses eight independent predictors of inferior survival: age >65 years, hemoglobin <10 g/dL, leukocytes >25 × 10⁹/L, circulating blasts ≥ 1%, constitutional symptoms, red cell transfusion dependency, platelet count <100 × 10⁹/L, and unfavorable karyotype (i.e., complex karyotype or sole or two abnormalities that include +8, -7/7q-, i(17q), inv(3), -5/5q-, 12p-, or 11q23 rearrangement). The presence of 0, 1, "2 or 3," and ≥ 4 adverse factors defines low, intermediate-1, intermediate-2, and high-risk disease with median survivals of approximately 15.4, 6.5, 2.9, and 1.3 years, respectively. A >80% two-year mortality is predicted by monosomal karyotype, inv(3)/i(17q) abnormalities, or any two of circulating blasts >9%, leukocytes ≥ 40 × 10⁹/L or other unfavorable karyotype. Most recently, mutations involving ASXL1, SRSF2, EZH2, and IDH1/2 or increased plasma IL-2R, IL-8, or serum-free light chain levels have been shown to adversely affect survival.
RISK-ADAPTED THERAPY: Observation alone is adequate for asymptomatic low/intermediate-1 risk disease. Allogeneic stem cell transplantation (ASCT) is often considered for high risk disease. Conventional or experimental drug therapy is reasonable for symptomatic intermediate-1 or intermediate-2 risk disease; however, ASCT is an acceptable treatment option for such patients in the presence of ASXL1 or other prognostically adverse mutations. Splenectomy and low-dose radiotherapy are used for drug-refractory splenomegaly. Radiotherapy is also used for the treatment of non-hepatosplenic EMH, PMF-associated pulmonary hypertension, and extremity bone pain.
Authors:
Ayalew Tefferi
Related Documents :
19652577 - Phase i trial of zoledronic acid + imatinib mesylate (gleevec) in patients with bone me...
23792567 - Folfiri plus dulanermin (rhapo2l/trail) in a patient with braf-mutant metastatic colon ...
3355647 - Morphometric study of bone marrow in chronic lymphocytic leukemia.
23200197 - Prognostic factors in merkel cell carcinoma: analysis of 240 cases.
24129427 - Post-chemoradiation anastomotic recurrence in locally advanced rectal cancer: no increa...
16849217 - Infectious disease control using contact tracing in random and scale-free networks.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of hematology     Volume:  88     ISSN:  1096-8652     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-25     Completed Date:  2013-03-22     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  141-50     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. tefferi.ayalew@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use
Bone Marrow / pathology
Decision Trees
Diagnosis, Differential
Drug Resistance, Neoplasm
Drugs, Investigational / therapeutic use
Humans
Janus Kinase 2 / genetics,  metabolism
Mutation
Primary Myelofibrosis / diagnosis*,  genetics,  pathology,  therapy*
Prognosis
Radiotherapy
Receptors, Thrombopoietin / genetics,  metabolism
Repressor Proteins / genetics,  metabolism
Splenectomy
Stem Cell Transplantation
Chemical
Reg. No./Substance:
0/ASXL1 protein, human; 0/Antineoplastic Agents; 0/Drugs, Investigational; 0/Receptors, Thrombopoietin; 0/Repressor Proteins; 143641-95-6/MPL protein, human; EC 2.7.10.2/JAK2 protein, human; EC 2.7.10.2/Janus Kinase 2
Comments/Corrections
Erratum In:
Am J Hematol. 2013 May;88(5):437-45

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MD...
Next Document:  Analysis of Mogroside V in Siraitia grosvenorii with Micelle-mediated Cloud-Point Extraction.